Oleclumab Biosimilar – Anti-NT5E, CD73 mAb – Research Grade

Introduction to Oleclumab Biosimilar – Anti-NT5E, CD73 mAb – Research Grade Oleclumab Biosimilar – Anti-NT5E, CD73 mAb – Research Grade is a novel monoclonal antibody (mAb) that targets the enzyme CD73, also known as ecto-5′-nucleotidase. This biosimilar is a highly specific and potent therapeutic agent that has shown promising results in preclinical studies for the treatment of various diseases, including cancer and autoimmune disorders.

Structure of Oleclumab Biosimilar

Oleclumab Biosimilar is a fully humanized IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It is produced using recombinant DNA technology and has a similar structure to the original Oleclumab, a monoclonal antibody developed by MedImmune.

The antibody consists of two identical heavy chains and two identical light chains, connected by disulfide bonds. The heavy chains contain a variable region (VH) and a constant region (CH), while the light chains contain a variable region (VL) and a constant region (CL). The VH and VL regions together form the antigen-binding site, which is responsible for the specific recognition and binding of CD73.

Activity of Oleclumab Biosimilar

CD73 is an enzyme that is involved in the conversion of extracellular adenosine monophosphate (AMP) into adenosine, a potent immunosuppressive molecule. This process is crucial for maintaining immune homeostasis, but it has also been shown to play a role in the development and progression of cancer and autoimmune disorders.

Oleclumab Biosimilar specifically binds to CD73, inhibiting its enzymatic activity and preventing the production of adenosine. This leads to an increase in extracellular AMP levels, which can activate immune cells and enhance anti-tumor immune responses. Additionally, the inhibition of adenosine production can reduce the immunosuppressive effects of the tumor microenvironment, making it more susceptible to immune attack.

Application of Oleclumab Biosimilar

Oleclumab Biosimilar has shown promising results in preclinical studies for the treatment of various types of cancer, including breast, lung, and colon cancer. It has also shown potential for the treatment of autoimmune disorders such as rheumatoid arthritis and multiple sclerosis.

In a preclinical study, Oleclumab Biosimilar was found to enhance the anti-tumor activity of other immunotherapies, such as checkpoint inhibitors, leading to improved tumor control and survival rates. This suggests that it could be used in combination with other therapies to enhance their effectiveness.

Furthermore, Oleclumab Biosimilar has also been shown to have a good safety profile, with no significant adverse effects observed in preclinical studies. This makes it a promising candidate for further clinical development as a potential treatment option for cancer and autoimmune disorders.

Conclusion

In summary, Oleclumab Biosimilar – Anti-NT5E, CD73 mAb – Research Grade is a novel monoclonal antibody that specifically targets the enzyme CD73. Its unique mechanism of action, inhibition of adenosine production, has shown promising results in preclinical studies for the treatment of cancer and autoimmune disorders. With its potential to enhance anti-tumor immune responses and its good safety profile, Oleclumab Biosimilar has the potential to become a valuable therapeutic option for patients in need. Further clinical studies are needed to fully evaluate its efficacy and safety in humans.